Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e13-7. doi: 10.1016/j.clml.2013.08.005. Epub 2013 Oct 19.
No abstract available

Keywords: Acute myeloid leukemia; Clofarabine; FLT3 inhibitors; FLT3 mutation; Sorafenib.

Publication types

  • Case Reports

MeSH terms

  • Adenine Nucleotides / administration & dosage*
  • Adult
  • Arabinonucleosides / administration & dosage*
  • Clofarabine
  • Cytarabine / administration & dosage*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives*
  • Phenylurea Compounds / administration & dosage*
  • Sorafenib
  • Tandem Repeat Sequences / genetics*
  • Young Adult
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Adenine Nucleotides
  • Arabinonucleosides
  • Phenylurea Compounds
  • Cytarabine
  • Niacinamide
  • Clofarabine
  • Sorafenib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3